Analysts Set Expectations for BioVie Q3 Earnings

BioVie Inc. (NASDAQ:BIVI) – Research analysts at Brookline Capital Management issued their Q3 2025 earnings estimates for shares of BioVie in a research report issued on Tuesday, March 18th. Brookline Capital Management analyst T. Bussian anticipates that the company will earn ($0.32) per share for the quarter. Brookline Capital Management has a “Strong-Buy” rating on the stock. Brookline Capital Management also issued estimates for BioVie’s Q4 2025 earnings at ($0.39) EPS, FY2025 earnings at ($1.34) EPS, Q1 2026 earnings at ($0.50) EPS, Q2 2026 earnings at ($0.56) EPS, Q3 2026 earnings at ($0.33) EPS, Q4 2026 earnings at ($0.23) EPS and FY2026 earnings at ($1.63) EPS.

BioVie (NASDAQ:BIVI) last released its quarterly earnings results on Tuesday, February 11th. The company reported ($0.46) earnings per share for the quarter.

BioVie Stock Performance

BIVI opened at $1.15 on Friday. The stock has a fifty day moving average of $1.62 and a 200-day moving average of $2.13. The company has a market capitalization of $21.22 million, a P/E ratio of -0.12 and a beta of 0.51. BioVie has a fifty-two week low of $0.99 and a fifty-two week high of $7.50.

Institutional Trading of BioVie

Institutional investors have recently bought and sold shares of the business. NewEdge Advisors LLC increased its holdings in shares of BioVie by 14,000.0% during the fourth quarter. NewEdge Advisors LLC now owns 14,100 shares of the company’s stock worth $28,000 after purchasing an additional 14,000 shares during the period. Squarepoint Ops LLC bought a new position in BioVie during the 4th quarter worth $28,000. Northern Trust Corp acquired a new position in BioVie in the 4th quarter valued at $34,000. Two Sigma Investments LP bought a new stake in shares of BioVie during the 4th quarter valued at $57,000. Finally, Prosperity Wealth Management Inc. bought a new stake in shares of BioVie during the 4th quarter valued at $63,000. Institutional investors own 4.59% of the company’s stock.

About BioVie

BioVie Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease.